# Tango Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights
Canonical URL: https://biopharmsignal.com/news/TNGX/tango-therapeutics-reports-first-quarter-2026-financial-results-and-provides-business-highlights
Ticker: TNGX
Company: Tango Therapeutics
Source: Tango Therapeutics
Published: 2026-05-13 20:08 EST
Original Source URL: https://ir.tangotx.com
## Summary

First clinical data from PRMT5/RAS(ON) combination trial to be pre sented in 2026 Cash position of $380 million as of March 31, 2026, with runway into 2028 beyond anticipated key data inflection points BOSTON, May 13, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc.

## Article Body
First clinical data from PRMT5/RAS(ON) combination trial to be pre sented in 2026 Cash position of $380 million as of March 31, 2026, with runway into 2028 beyond anticipated key data inflection points BOSTON, May 13, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc.
## Recent Company News
- 2026-05-13 20:08 EST — [Tango Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights](https://biopharmsignal.com/news/TNGX/tango-therapeutics-reports-first-quarter-2026-financial-results-and-provides-business-highlights) — Source: Tango Therapeutics
- 2026-05-04 20:31 EST — [Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/TNGX/tango-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4) — Source: Tango Therapeutics
- 2026-04-15 13:05 EST — [Tango Therapeutics Announces Leadership Appointments to Accelerate Late-Stage Development of Vopimetostat](https://biopharmsignal.com/news/TNGX/tango-therapeutics-announces-leadership-appointments-to-accelerate-late-stage-development-of-vopimetostat) — Source: Tango Therapeutics
- 2026-03-05 12:00 EST — [Tango Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights](https://biopharmsignal.com/news/TNGX/tango-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-highlights) — Source: Tango Therapeutics
- 2026-02-18 12:00 EST — [Tango Therapeutics to Report Fourth Quarter 2025 Financial Results and Participate in Three Upcoming Investor Conferences](https://biopharmsignal.com/news/TNGX/tango-therapeutics-to-report-fourth-quarter-2025-financial-results-and-participate-in-three-upcoming-investor-conferences) — Source: Tango Therapeutics
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)